{
    "clinical_study": {
        "@rank": "126175", 
        "arm_group": [
            {
                "arm_group_label": "Macrobead Implantation Arm", 
                "arm_group_type": "Experimental", 
                "description": "patients who will undergo up to 4 implantations of RENCA macrobeads, at an amount of 8 RENCA macrobeads /kg body weight"
            }, 
            {
                "arm_group_label": "Best Supportive Care Arm", 
                "arm_group_type": "No Intervention", 
                "description": "patients who will receive, or are receiving, best supportive care, defined as management of symptoms aimed at maintaining or improving quality of life, but not including approved therapies targeting the patient's malignancy"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a clinical research study of an investigational (FDA IND-BB 10091) treatment for\n      patients with  advanced colorectal cancer that no longer responds to standard therapies.\n\n      The treatment is being evaluated for its effect on tumor growth. It consists of small beads\n      that contain mouse cancer cells from a mouse kidney cancer cell line. The cells in the beads\n      produce substances that have been shown to slow or stop the growth of tumors in experimental\n      animals, veterinary patients, and 37 humans with colorectal cancers in a Phase 1 and 2\n      safety trials."
        }, 
        "brief_title": "Nonrandomized, Open-Label Phase IIb Efficacy Trial of Cancer Macrobeads Compared With Best Supportive Care in Patients With Treatment-Resistant Colorectal Cancer", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Cancers", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a Phase IIb, multicenter, nonrandomized, open-label study with RENCA macrobeads in\n      patients with treatment-resistant, metastatic colorectal carcinoma to determine the effect\n      of RENCA macrobead implantation on overall survival compared with best supportive care.\n\n      Two treatment groups will be enrolled in this study, as follows:\n\n        -  Group A (n=40) - patients who will undergo up to 4 implantations of RENCA macrobeads,\n           at an amount of 8 RENCA macrobeads /kg body weight\n\n        -  Group B (n=80) - patients who will receive or are receiving best supportive care,\n           defined as management of symptoms aimed at maintaining or improving quality of life,\n           but not including approved therapies targeting the patient's malignancy"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients in both treatment groups must meet all of the following criteria to be considered\n        eligible to participate in the study:\n\n          -  Adult men or women, aged 18 years or older, with histologically-confirmed, metastatic\n             adenocarcinoma of the colon or rectum that is resistant to available treatment\n             options\n\n          -  Radiographically documented evidence of disease progression.\n\n          -  Life expectancy of at least 6 weeks, in the investigator's opinion, at the time\n             disease progression is documented.\n\n          -  Considered surgical candidates on the basis of co-morbidity risks, number and sites\n             of metastases, and ability to withstand general anesthesia.\n\n          -  Able to provide written informed consent.\n\n        Patients in Group A must also meet all of the following additional criteria:\n\n          -  ECOG performance status score of 0, 1, or 2.\n\n          -  Adequate hematologic function, defined as follows:\n\n               1. absolute neutrophil count (ANC) \u22651500 /mL\n\n               2. hemoglobin \u22659 g/dL\n\n               3. platelets \u226575,000 /mL\n\n          -  Adequate hepatic function, defined as follows:\n\n               1. bilirubin \u22641.5 times the upper limit of normal (x ULN)\n\n               2. aspartate transaminase (AST) \u22643 x ULN, or \u22645 x ULN if liver metastases are\n                  present\n\n               3. alanine transaminase (ALT) \u22643, x ULN, or \u22645 x ULN if liver metastases are\n                  present\n\n          -  Adequate renal function, defined as creatinine \u22642.0 mg/dL.\n\n          -  Adequate coagulation function, defined as follows:\n\n               1. International Normalized Ratio (INR) \u22641.5 or between 2 and 3 if the patient is\n                  receiving anticoagulation\n\n               2. partial thromboplastin time (PTT) \u22645 seconds above the ULN Note: Patients\n                  receiving full-dose anticoagulation therapy must be receiving a stable dose of\n                  oral anticoagulant therapy or low-molecular-weight heparin.\n\n          -  Clinically significant toxic effects of chemotherapy (excluding alopecia),\n             radiotherapy, hormonal therapy, or prior surgery must have resolved to Grade 1 or\n             better, with the exception of peripheral neuropathy, which must have resolved to\n             Grade 2 or better.\n\n          -  Agrees to contraceptive use while on study if sexually active\n\n        Exclusion Criteria:\n\n        Patients in either treatment group who meet any of the following criteria will be excluded\n        from participating in the study:\n\n          -  Hepatic blood flow abnormalities, i.e., portal vein hypertension and thrombosis,\n             and/or a large volume of ascites.\n\n          -  Concurrent cancer of any other type, except skin cancers other than melanoma.\n\n          -  A positive test result for HIV or any hepatitis other than A at screening.\n\n          -  Considered by the investigator to be unsuitable for participation in the study\n\n        Patients in Group A who meet any of the following criteria will be excluded from\n        participating in the study:\n\n          -  Received FDA-approved chemotherapy within 3 weeks of Day 0, or bevacizumab (or\n             similar drugs) within 4 weeks of Day 0, or radiation therapy at any site within 4\n             weeks of Day 0\n\n          -  Investigational anticancer therapy within 4 weeks of Day 0\n\n          -  Positive reaction to the skin test for allergy to mouse antigen\n\n          -  History of hypersensitivity reaction that, in the opinion of the investigator, poses\n             an increased risk of an allergic reaction to the RENCA macrobeads, particularly any\n             known allergy to murine antigens or body tissues.\n\n          -  Ongoing or active infection, symptomatic congestive heart failure, unstable angina\n             pectoris, serious cardiac arrhythmias (with the exception of well controlled atrial\n             fibrillation), active bleeding, or psychiatric illness, or social situations that\n             could interfere with the patient's ability to participate in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02046174", 
            "org_study_id": "RI-MB-203", 
            "secondary_id": "1310014396"
        }, 
        "intervention": {
            "arm_group_label": "Macrobead Implantation Arm", 
            "intervention_name": "RENCA macrobeads", 
            "intervention_type": "Biological", 
            "other_name": [
                "mouse renal adenocarcinoma (RENCA) macrobeads", 
                "macrobead"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "colon", 
            "colorectal", 
            "rectal", 
            "cancer", 
            "macrobead", 
            "stage IV", 
            "metastatic", 
            "biological", 
            "mouse cells", 
            "new york", 
            "new jersey", 
            "clinical research"
        ], 
        "lastchanged_date": "April 23, 2014", 
        "link": [
            {
                "url": "http://rogosin.org/cancer"
            }, 
            {
                "url": "http://rogosin.org/medical-research-education/medical-research-education-cancer.php"
            }
        ], 
        "location": [
            {
                "contact": {
                    "email": "ccomfort@calvaryhospital.org", 
                    "last_name": "Christopher Comfort, MD", 
                    "phone": "718-518-2210"
                }, 
                "facility": {
                    "address": {
                        "city": "Bronx", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10461"
                    }, 
                    "name": "Calvary Hospital"
                }, 
                "investigator": {
                    "last_name": "Christopher Comfort, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jot9093@nyp.org", 
                    "last_name": "Joanne Thomas, RN, MSN, MPH", 
                    "phone": "212-746-9233"
                }, 
                "contact_backup": {
                    "email": "tap9030@nyp.org", 
                    "last_name": "Tapan Parikh, MBBS, MPH", 
                    "phone": "212-746-0073"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "The Rogosin Institute"
                }, 
                "investigator": [
                    {
                        "last_name": "Barry H. Smith, M.D., Ph.D", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Allyson Ocean, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Nathaniel Berman, M.D.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase IIb, Nonrandomized, Open-Label Trial With Mouse Renal Adenocarcinoma (RENCA) Cell Containing Agarose-Agarose Macrobeads Compared With Best Supportive Care in Patients With Treatment-Resistant, Metastatic Colorectal Carcinoma", 
        "other_outcome": {
            "description": "Safety and tolerability of RENCA macrobeads, as measured by the following:\nadverse events\nclinical laboratory tests, including chemistry, hematology, coagulation, urinalysis, and test for presence of ecotropic murine leukemia virus (eMuLV)\nmurine allergen skin test", 
            "measure": "Number of Participants with Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "overall_contact": {
            "email": "bas2005@nyp.org", 
            "last_name": "Barry H. Smith, M.D., Ph.D", 
            "phone": "212-746-1551"
        }, 
        "overall_contact_backup": {
            "email": "nab2009@nyp.org", 
            "last_name": "Nathaniel Berman, M.D.", 
            "phone": "212-746-9766"
        }, 
        "overall_official": [
            {
                "affiliation": "The Rogosin Institute", 
                "last_name": "Barry H Smith, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "The Rogosin Institute", 
                "last_name": "William E. Gannon, Jr, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This study is to evaluate the efficacy of renal adenocarcinoma (RENCA) macrobead implantation compared with best supportive care, as assessed by overall survival", 
            "measure": "Overall Survival", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02046174"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change from baseline over the period after the first RENCA macrobead implantation in levels of tumor markers (including carcinoembryonic antigen [CEA] and carbohydrate antigen 19-9 [CA19-9]", 
                "measure": "Change in levels of tumor markers (CEA and CA19-9)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Change from baseline over the period after the first RENCA macrobead implantation in clinical status, as measured by Eastern Cooperative Oncology Group (ECOG) performance status score and Global Clinical Assessment", 
                "measure": "Change in clinical status, as measured by ECOG performance status score and Global clinical assessment", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Change from baseline over the period after the first RENCA macrobead implantation in quality of life, as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30)", 
                "measure": "Change in quality of life, as measured by the EORTC QLQ C30 Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Tumor marker response rate, defined as the proportion of patients who have a decrease from baseline of 20% or more in CEA or CA 19-9 values", 
                "measure": "Tumor marker response rate", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Change from baseline over the period after the first RENCA macrobead implantation in quality of life, as measured by the Karnofsky Performance Status Scale (KPS)", 
                "measure": "Change in quality of life, as measured by the KPS", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "The Rogosin Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The Rogosin Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}